Clinical Trials | April 08, 2026
Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy
The trial also demonstrated significant improvements across multiple secondary endpoints
The trial also demonstrated significant improvements across multiple secondary endpoints
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Subscribe To Our Newsletter & Stay Updated
